Brief: Viva Biotech Passing Of U.S. FDA On-Site Inspection By Langhua Pharmaceutical
27/03/2025 12:43
March 27 (Reuters) - VIVA Biotech Holdings 1873.HK: PASSING OF U.S. FDA ON-SITE INSPECTION BY LANGHUA PHARMACEUTICAL Further company coverage: 1873.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on VIVA Biotech Holdings
See all newsVIVA Biotech H1 profit falls on weaker investment income, FX headwinds
Brief: Viva Biotech Posts FY Net Profit RMB269.3 Million
Brief: Viva Biotech Received Declaration Letter
Brief: Viva Biotech Says Hangzhou Viva Zongchen Agreed To Invest RMB25.0 Million To Fund
Brief: Viva Biotech Passing Of U.S. FDA On-Site Inspection By Langhua Pharmaceutical